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Objectives: To estimate the incremental cost-effectiveness ratio (ICER) of dual-
mobility cups (MBH) when used instead of conventional cups (FBH) to help reduce 
dislocation rates following total hip replacement (THR) in France. MethOds: A 
Markov model simulated two cohorts of patients: one with MBH and one with FBH. 
Three different states of health were considered: “stable”, “dislocation/revision” and 
“death”. The model adopted a collective perspective and the time horizon of the 
model was lifetime. Dislocation/revision rates were estimated using two different 
sources: literature review and expert opinions (analysis 1) and analysis of the PMSI 
(French hospital database) of Patients having one THR in 2009 followed through the 
end of 2012 (analysis 2). Costs considered were hospitalization costs (reduction/
revision for dislocation performed in acute care unit and care in rehabilitation 
units), valued using the National Scale Costs with Common methodology (ENCC). 
Outpatients’ costs were considered for patients going back home after hospitaliza-
tion and valued by expert opinions and literature data. The model estimated the 
number of dislocations/revisions for each cohort and differences between the two 
groups in terms of QALY gained, costs and cost-effectiveness ratio. Deterministic 
and probabilistic sensitivity analyses (PSA) were conducted. Results: In analysis 
1 for a 100,000 THR cohort, 4,626 dislocations and 1,243 revisions were avoided. 
Total number of QALY gained was 894 and total economic gain € 44.7 million. In 
analysis 2, 3, 176 dislocations and 854 revisions were avoided for an economic gain 
of € 30.7 million and a gain of 611 QALY. Reported to 100,000 THR, the economic gain 
per MBH cup was € 447 or € 307. PSA estimated the mean ICER to € -55,693 per QALY 
gained. cOnclusiOns: Because of the current rules of tariffs used in France and 
given the absence of additional costs associated with the use of DM prosthesis, this 
strategy can be considered dominant in THR.
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Objectives: The purpose of this study was to estimate the cost-effectiveness of 
multiple anti-osteoporotic drug therapies for secondary prevention of fractures in 
elderly women with osteoporosis in Japan. MethOds: A state transition model 
with nine health states (seven types of post-fracture, bedridden, and death) was 
developed to predict lifetime costs and quality-adjusted life years (QALY) of no anti-
osteoporotic therapy and eight drug therapies in patients with a previous vertebral 
fracture. Incidence of hip, vertebral, and other fracture associated with age and 
bone mineral density (BMD) was estimated by using a regression approach based 
on epidemiologic studies in Japan. Comparative effectiveness of anti-osteoporo-
tic drug therapies was derived from a published network meta-analysis. For the 
base-case analysis, we ran the model with T-score of -2.5 and different age (65, 70, 
and 75 years). Probabilistic sensitivity analysis was performed to assess param-
eter uncertainty. Results: Alendronate therapy dominated all other strategies, 
resulting in 11.746 QALY and lifetime costs of $34,568. Compared to no preventive 
therapy, alendronate conferred an additional 0.458 QALY and saved lifetime costs of 
$13,753. Risedronate was equally cost-effective, resulting in 11.731 QALY and costs 
of $34,932. Applying a willingness to pay threshold of $50,000 per QALY, the prob-
ability of being cost-effective were estimated to 76.2 % and 23.8% for alendronate 
and risedronate, respectively. These results did not change in women aged 70 and 75 
years. cOnclusiOns: Bisphosphonate therapies for secondary prevention of frac-
tures in elderly women would be cost-effective in terms of Japan health care system.
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Objectives: Evaluate most rationale medical technology in the rheumatoid 
arthritis therapy (RA) (comparison of alternatives – GEBDs Tofacitinib and bio-
logics: Infliximab, Abatacept, Certolizumab pegol, Golimumab, Adalimumab and 
Tocilizumab) from pharmacoeconomic analysis point of view. MethOds: Analysis 
based on the assessment for one statistically average patient suffering from RA, 
and weighing 70 kilograms, over a one year course of treatment (52 weeks). The 
analysis done of direct costs included: cost of DMARDs and biologics therapy use; 
costs of drug introduction; physician visits cost. Cost-minimization and missed 
opportunities analysis were used. Results: During the effectiveness analysis 
of RA treatment, based on the meta-analyses of randomized placebo-controlled 
trials data (including meta-analyses P. Kawalec, 2013; E. Salgado, 2013), Russian 
and international RA treatment recommendations, it was concluded that there 
was no statistically significant difference in efficacy and toxicity of the Tofacitinib 
and the biologics used in the RA treatment. One year treatment course with 
Tofacitinib, Infliximab, Abatacept, Golimumab, Certolizumab pegol, Adalimumab 
and Tocilizumab cost, include subcutaneous route of administration, will amount 
to 12.818 EUR, 20.932 EUR, 14.855 EUR, 18.104 EUR, 19.642 EUR, 20.120 EUR and 21.664 
EUR, respectively. cOnclusiOns: During pharmacoeconomic analysis was defined 
that therapy with Tofacitinib in comparison with biologics use will reduce the cost 
of a one year course of treatment for each RA patient from 2.037 EUR to 8.846 EUR. 
Transition of 100 RA patients onto a treatment regimen, includes Tofacitinib use, 
will make it possible to treat from 15 to 69 patients more suffering from this disease.
PMS52
rEhAbilitAtion in rESurfACing hiP ArthroPlASty PAtiEntS: 
PrEliMinAry CoSt-EffECtivEnESS rESultS froM A CliniCAl triAl
Fusco F.1, Campbell H.2, Newman M.3, Barker K.2
1Scuola Superiore Sant’Anna, Pisa, Italy, 2University of Oxford, Oxford, UK, 3University of Oxford, 
Oxford, UK., UK
to measure quality of life. The clinical parameters used in the model take into 
account the results from a MTC of clinical trials. In order to adapt the model to 
the Portuguese context, several adjustments were made to its original version. 
These mainly relate to mortality rates by gender and to the unit costs of medical 
resources, such as drugs, medical visits, admissions, ancillary tests and so on, 
that were obtained from public official sources. We applied a 5% discount rate and 
conducted an analysis for a hypothetical cohort of 1,000 patients. Results: The 
treatment of RA with etanercept is more expensive than that with the comparator. 
Nevertheless, QALYs gained do compensate for the additional costs. Overall, ICER 
is € 12,853, which is below the usual willingness to pay threshold used in Portugal. 
A sensitivity analysis was carried out, which confirmed the robustness of these 
results. cOnclusiOns: According to our analysis, etanercept is a cost-effective 
alternative versus golimumab for the treatment of rheumatoid arthritis. Its main 
advantage over the selected comparator relates to the associated improvements 
in health related quality of life.
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Objectives: To determine the cost-effectiveness of pegloticase (Krystexxa®) for 
patients with severe debilitating chronic tophaceous gout (SDCTG), from a UK health 
care perspective. MethOds: Severe debilitating chronic tophaceous gout (SDCTG) 
is a debilitating disease, with high unmet medical need. Existing treatments mainly 
provide symptom relief and do not modify the disease course. Pegloticase has the 
potential to be a disease modifying agent. A decision analytical model was built to 
compare the use of pegloticase in patients with SDCTG with best supportive care 
(BSC) with a Markov model used to extrapolate outcomes to a 20 year time-horizon. 
In the basecase, the disease modifying properties of pegloticase were modelled. 
In scenario analyses only symptomatic relief of pegloticase on acute attacks and 
tophi was included. Results: In the basecase, the cost-effectiveness of pegloti-
case compared to BSC was £31,027 per QALY gained. In this basecase, pegloticase 
dramatically reduced the uric acid burden in over 60% of patients who completed a 
six month course and were assumed could then be controlled on xanthine oxidase 
inhibitor maintenance treatment. In a pessimistic scenario whereby pegloticase was 
assumed to only provide symptomatic relief, the ICER was £48,672/QALY gained. In a 
further scenario whereby utility benefits were limited to only short-term reduction 
in acute flares and presence of tophi, the ICER was £54,345/QALY. Apart from these 
two drivers, the cost-effectiveness estimates were relatively stable across a range 
of sensitivity analyses. cOnclusiOns: In the context of a highly severe and debili-
tating form of gout, with small patient numbers and a lack of alternative effective 
treatment options, pegloticase can be considered good value-for-money. Further 
clinical evidence is required to demonstrate the disease modifying properties of 
pegloticase. However, such data collection and hence the ability to perform robust 
economic evaluations for HTA purposes is difficult especially when the sponsoring 
company is small with limited funds.
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Objectives: The prevalent vertebral fracture (VF) is a risk factor for future VF, which 
can be decreased with drug therapy. However, most VFs are not recognized clinically. 
Vertebral fracture assessment (VFA) by dual-energy x-ray absorptiometry (DXA) and 
spine x-ray can be performed to detect these prevalent VFs. This study aimed to 
estimate the costs, effectiveness, and radiation exposure of VF diagnostic strate-
gies. MethOds: Markov model over a 10-year period was used to calculate the 
medical costs for diagnostic tests and VF treatment, the reduction of incident VFs 
of patients who have experienced a VF, and the radiation doses in target population 
aged over 50. We compared three strategies: ‘VFA followed by confirmatory radi-
ography (VFA screening)’, ‘only VFA’ and ‘only x-ray’ every 2 years, to ‘no screening 
before recognition’. We assumed that all patients tested positive for VF received drug 
therapy. A discount rate of 5% was applied in cost. Results: The results showed the 
incremental costs for women over age 50 who had VFA screening, only VFA, and only 
x-ray were $1,112, $1,546, and $1,270 per person, respectively. Future VF incidence 
was reduced by 29% in both VFA screening and only VFA and 35% in only x-ray as 
compared with no screening for 10 years. Radiation exposure was highest in the 
only x-ray strategy. Also, the effectiveness and medical costs were more increased 
in female and old age people than in male and over age 50. The sensitivity analyses 
showed that these results are robust to variety assumptions including cycle length, 
medical costs, and diagnostic accuracy. cOnclusiOns: This study suggests that 
VFA screening strategy can be relevant option for new VF prevention as considering 
lower cost and less radiation. This study is expected to provide useful information 
as establishing the VF diagnostic strategy in clinical practice.
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that CZP+MTX seems to be a cost-effective alternative when compared to approved 
subcutaneous anti-TNFs for the management of RA in Greece.
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Objectives: Osteoporotic fractures are common in older adults and are often asso-
ciated with high morbidity and mortality. As the incidence increases with age, it 
is natural that osteoporotic fractures have become a major health problem world-
wide. Increasing number of patients with osteoporotic fracture will have a serious 
economic impact on the patient themselves and the society. The objective of 
this study is to study the cost-effectiveness of strontium ranelate compared 
to alendronate for patients with post-menopausal osteoporotic fractures in 
Malaysia. MethOds: A Markov model was developed to project clinical and eco-
nomic benefits of strontium in a hypothetical cohort of patients (N= 1,000) over a 
5-year time horizon. This study was conducted from a payer perspective. Model 
parameters including transition probabilities and costs of treating fracture at vari-
ous sites were Malaysia-specific. Drug costs were obtained from a public teach-
ing hospital in Kuala Lumpur. Utilities were derived from previous literatures and 
efficacy data were derived from two pivotal trials, i. e. SOTI and TROPOS trials. 
Outcomes were presented as cost per quality-adjusted life year (QALY) gained. A 
discount rate of 3% was applied. Both 1-way and multivariate probabilistic sen-
sitivity analyses were undertaken to evaluate robustness of results. Results: 
Compared to alendronate, strontium could prevent 328 wrist, 192 hip, 7 vertebra 
and 115 multiple fractures respectively over 5 years, which was translated into 
27.9 QALYs gained. Using strontium can lead to cost reduction of MYR1,416,595 
(USD442,685), MYR478,257 (USD149,455), MYR22,784 (USD7,120) and MYR61,883 
(USD113,088) due to reduced episodes of fractures at wrist/hip/vertebra/multi-
ple sites respectively. The total reduction of direct medical costs of MYR2,279,519 
(USD712,349) was larger than the extra drug cost, hence making strontium a cost-
saving therapy. cOnclusiOns: It was shown that strontium appeared to be more 
cost-effective compared to alendronate and hence should be recommended in the 
public sector in Malaysia.
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Objectives: To evaluate the cost-effectiveness of MabThera in patients with severe 
GPA and MPA in the United Kingdom (UK). bAckgROund: In March 2014 NICE 
issued positive guidance for the use of MabThera in patients with severe GPA and 
MPA [TA 308]. MethOds: An economic model was developed to reflect the health 
care system and the current treatment pathway in the UK. The cost-effectiveness 
analysis employs a Markov model with four health states: complete remission, 
non- remission, uncontrolled disease and death. Patients were assumed to start in 
the non-remission health state, transitioning based on their response to treatment. 
Relapsing patients who have exhausted all available treatment options they are 
assumed to enter the uncontrolled disease health state where they remain until 
death. The efficacy data for the intervention and comparator arm were taken from 
the RAVE study (Stone et al 2010) which demonstrated that MabThera was non-
inferior to cyclophosphamide (CYC). In a subgroup of patients who had received 
prior therapy, MabThera was superior to CYC. Benefits were expressed as QALYs. 
Costs were calculated from a National Health Service and Personal Social Services 
perspective. The analysis calculated incremental costs and benefits associated with 
the addition of MabThera to the treatment paradigm which was assumed to consist 
of CYC and azathioprine. For patients intolerant to CYC, MabThera was assumed to 
substitute for CYC. The RAVE trial reports health related quality of life using SF-36. 
The SF-36 scores were converted to EQ-5D in a post-hoc analysis using a published 
model [Ara and Brazier 2008]. Results: Base case results estimated incremental 
costs of approximately £3,700 and incremental QALYs of 0.306. The incremental 
cost-effectiveness ratio (ICER) was £12,100 per QALY gained. cOnclusiOns: The 
results of this analysis suggest that MabThera is a cost-effective treatment for severe 
GPA and MPA.
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Objectives: To assess the indirect costs of RA, CD and Ps in an employed population 
in Poland. MethOds: Data on presenteeism and absenteeism related with analyzed 
diagnoses were collected in a cross-sectional study from patients of ambulatory 
specialist care around Poland (30 rheumatology, 30 dermatology and 29 gastroenter-
ology centers). Lost productivity was measured with Work Productivity and Activity 
Impairment (WPAI) questionnaire and patients’ disease activity was assessed on 
standardized, disease specific scales (DAS28, PASI, and CDAI). 328 (RA), 460 (Ps), 256 
(CD) working patients were included in the analyses conducted separately for each 
diagnosis. Unit cost of lost productivity was estimated using 2012 GDP per worker 
per hour corrected for diminishing marginal productivity and added up to PLN 
33.18. Results: Mean age of M2W respondents was 36 for CD, 42 for Ps and 46 for 
RA patients (only patients in productive age – 18-60/65 were included in the study). 
Objectives: A tailored accelerated physiotherapy (AP) program following 
Resurfacing Hip Arthroplasty (RHA) has been shown to be effective in improving hip 
function and range of motion in young male patients; however no evidence has been 
provided on its cost-effectiveness. The aim of this UK trial-based economic evalu-
ation was to assess the cost-effectiveness of AP versus a standard rehabilitation 
protocol (SRP). MethOds: Trial participants were randomized post-RHA to AP or 
SRP. The experimental arm followed an 8-week programme with no hip precautions, 
full-weight bearing from day one, tailored exercises and an additional physiotherapy 
session. The control group received the standard 8-week course of rehabilitation. At 
6, 16, and 52 weeks, patients reported primary and secondary health care contacts, 
use of equipment, and private health care contacts. These data were valued using 
2012/2013 national average unit costs. The 3-level EuroQol EQ-5D questionnaire was 
completed by patients at baseline, 6, 16 and 52 weeks and used to calculate Quality 
Adjusted Life Years (QALYs) to 12 months. Results: 80 young males (median age: 
55.8 years) were randomized to AP (n= 40) or SRP (n= 40). Preliminary results showed 
mean (SE) health care costs to 52 weeks were £375 (£76) in the AP arm and £612 (£150) 
in the SRP arm (mean (95% CI) difference -£237 (-£582 to £108)). There were more 
visits to secondary care and primary care practitioners in the SRP arm. Mean (SE) 
QALYs were 0.84 (0.02) with AP and 0.72 (0.03) with SRP (mean (95% CI) difference 
0.12 (0.04 to 0.21)). The probability that AP is cost-effective at a maximum willing-
ness to pay of £20,000 per QALY is 99%. cOnclusiOns: From the perspective of the 
health care provider, a tailored accelerated physiotherapy programme for younger 
male patients undergoing RHA appears cost-effective when compared to a standard 
rehabilitation programme.
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Objectives: The aim of this study is evaluation of the effectiveness and cost-
effectiveness of using rituximab as first line of treatment for patients with refrac-
tory rheumatoid arthritis in comparison to continuing conventional DMARDs, 
from a perspective of health service governors. MethOds: A systematic review 
was implemented through searching PubMed, Scopus and Cochrane Library. 
Quality assessment was performed by JADAD questionnaire. After meta-analysis 
of ACR (American College of Rheumatology) index results, QALY (Quality Adjusted 
Life Years) gained were calculated through mapping ACR index to HAQ (Health 
Assessment Questionnaire) and utility index. To measure the direct and indirect 
medical costs, a set of interviews with patients were applied. Thirty two patients 
were selected from three referral rheumatology clinics in Tehran with definite diag-
nosis of refractory rheumatoid arthritis one year before, and treatment regimen of 
either rituximab or DMARDs within last year. Incremental cost-effectiveness ratio 
were calculated for a period of six months for base case and generic rituximab 
scenario. Three fold of GDP (Gross Domestic Product) per capita was considered as 
threshold of cost-effectiveness. Results: Four studies were eligible to be consid-
ered in this systematic review. Total risk difference of 0.3 for ACR20 criteria, 0.21 
for ACR50 and 0.1 for ACR70 were resulted from meta-analysis. Also mean of total 
medical costs of patients for 24 weeks were $3985 in rituximab group and $932 for 
DMARDs group in the base case analysis. Thus, the incremental cost per QALY ratio 
will be $45900 to $70223 in the base case, and $32386 to $49550 for generic scenario, 
while the threshold of cost-effectiveness was $21684. cOnclusiOns: Rituximab 
cannot be considered as cost-effective for the treatment of patients with refractory 
rheumatoid arthritis in Iran.
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Objectives: To evaluate the cost-effectiveness of certolizumab pegol (CZP) as an 
add-on therapy to methotrexate (MTX) versus etanercept, adalimumab or goli-
mumab in patients with moderate-to-severe active rheumatoid arthritis (RA) who 
did not respond adequately to conventional synthetic disease-modifying anti-rheu-
matic drugs (csDMARDs) including MTX in Greece. MethOds: A Markov model 
with a cycle length of 6 months was used to assess cost and health outcomes of 
CZP versus other TNF-α inhibitors recommended in Greece over a patient’s lifetime. 
On the discontinuation of first-line treatment with CZP or comparator, patients 
were switched to a second anti-TNF agent, and after failing that, they moved on to 
a third biologic agent with another mode of action. A sequential use of csDMARDs 
was assigned after the last biologic therapy. Clinical data and utility values were 
extracted from published literature. The analysis was conducted from a third-party 
payer perspective in Greece. Costs related to drug acquisition, administration, moni-
toring and patient management were considered (2014). All results were presented 
as incremental cost-effectiveness ratios (ICERs) per quality-adjusted life year (QALY). 
Probabilistic sensitivity analysis (PSA) was performed to ascertain the robustness of 
the base-case findings. Results: The base-case analysis indicated that compared 
with etanercept+MTX, CZP+MTX was cost-effective (ICER: € 3,177/QALY), and versus 
adalimumab or golimumab, CZP was the dominant strategy (less costly and more 
effective). For all comparisons, CZP treatment resulted in greater improvements in 
life expectancy and QALYs. PSA indicated that at the willingness-to-pay threshold 
of € 34,000 per QALY gained, CZP+MTX was associated with a 71.6%, 97.9% or 99.2% 
probability of being cost-effective versus etanercept, golimumab or adalimumab as 
combination therapies with MTX, respectively. cOnclusiOns: This analysis shows 
